Flemming Ornskov

19 results

Two sources with direct knowledge of the matter said last week that Takeda had sounded out its major creditors for loans to fund a potential Shire bid. Photograph: Suzanne Plunkett/Reuters
Shire sells cancer drugs to Servier for $2.4bn as Takeda circles

Shire, the Irish rare diseases specialist that is a potential takeover target for Japan’s Takeda Pharmaceutical, is selling its oncology business to (...)

Susan Hynes, Dunboyne site lead for Shire and Dominic Carolan, CEO NIBRT. Photograph: Conor McCabe
Pharma group Shire signs training deal for Dublin

Shire, the Ireland-domiciled pharma group that specialises in rare diseases, has signed a training deal with the National Institute of Bioprocessing R(...)

Shire said on Thursday that it was exploring options for its hyperactive drugs business. Photograph: Chris Ratcliffe/Bloomberg
Shire may spin off ADHD drugs business

Irish headquartered pharmaceutical company Shire said it was exploring options for its hyperactive drugs business, including a possible stock market l(...)

Shire acquired Baxalta, which was a US rival, in a so-called mega-merger worth about $32 billion last year. Photograph: Aidan Crawley/Bloomberg
Dublin-based Shire Pharmaceuticals sees earnings rise 14%

Earnings at Dublin-headquartered Shire Pharmaceuticals rose 14 per cent year on year during the first quarter of 2017 due to higher sales of rare dise(...)

The facility will use the latest bioprocessing techniques and will employ flexible production strategies to enable it to supply both clinical and commercial scale products
Shire receives planning permission for Co Meath plant

Pharma giant Shire has received formal planning permission for its new $400 million (€371 million)biologics manufacturing facility on a 120 acre site (...)

Drugmaker Shire: earnings per American depositary share, excluding some costs, will grow to between $12.70 and $13.10 this year including results from Baxalta. Photograph: Suzanne Plunkett/Reuters
Shire shares surge as drug group upgrades earnings guidance

Drugmaker Shire said the $32 billion takeover of US rival Baxalta will boost earnings and sales this year, sending its stock surging to the highest le(...)

BP’s chief executive Bob Dudley: BP shareholders voted on April 14 to oppose his $20 million pay package for 2015, the rare revolt reflecting outrage after the British oil and gas company recorded its biggest annual loss. Photograph: REUTERS/Suzanne Plunkett/Files
Perils of paying CEOs too much: When shareholders say no

Chief executives’ outsized pay packages are again coming under scrutiny, following a host of controversial pay awards in recent weeks. A fortnight ago(...)

The jobs at the facility will consist of ‘highly skilled and full time in the areas of R&D, operations, technical staff, engineering and construction’
Pharma group Shire to create 400 jobs in Co Meath

Pharma group Shire is create 400 jobs in Co Meath over the next four years as part of a $400 million investment in the Republic. The company said it (...)

Shire CEO Flemming Ornskov is optimistic about the deal with Baxalta, but can these two very different companies fuel growth? Photograph: Aidan Crawley/Bloomberg
Cantillon: Shire takeover of Baxalta fails to impress shareholders

Flemming Ornskov had reason to be pleased yesterday. The Shire CEO’s six-month pursuit of rival Baxalta appears finally to have reached a successful c(...)

Dublin-based Shire has agreed to buy Dyax Corp for about $5.9 billion to gain access to the drug developer’s late-stage experimental treatment for a dangerous inflammatory disease that can block breathing. (Photograph: Simon Dawson/Bloomberg)
Shire to buy Dyax for $5.9 bn

Dublin-based Shire has agreed to buy Dyax Corp for about $5.9 billion to gain access to the drug developer’s late-stage experimental treatment for a (...)

  • 1
  • 2
  • Next ›
  • Last »